Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.

Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T.

Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22.

2.

Effects of AHCC® on Immune and Stress Responses in Healthy Individuals.

Takanari J, Sato A, Waki H, Miyazaki S, Uebaba K, Hisajima T.

J Evid Based Integr Med. 2018 Jan-Dec;23:2156587218756511. doi: 10.1177/2156587218756511.

PMID:
29558822
3.

Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound.

Segarra S, Miró G, Montoya A, Pardo-Marín L, Teichenné J, Ferrer L, Cerón JJ.

Parasit Vectors. 2018 Feb 21;11(1):103. doi: 10.1186/s13071-018-2705-z.

4.

Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation.

Choi JY, Lee S, Yun SM, Suh DH, Kim K, No JH, Jeong EH, Kim YB.

Nutr Cancer. 2018 Jan;70(1):109-115. doi: 10.1080/01635581.2018.1380203. Epub 2017 Nov 7.

PMID:
29111786
5.

MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC).

Graham ÉA, Mallet JF, Jambi M, Nishioka H, Homma K, Matar C.

Cancer Biol Ther. 2017 Oct 3;18(10):765-774. doi: 10.1080/15384047.2017.1373211. Epub 2017 Sep 8.

6.

An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.

Diaz-Beveridge R, Bruixola G, Lorente D, Caballero J, Rodrigo E, Segura Á, Akhoundova D, Giménez A, Aparicio J.

Clin Transl Oncol. 2018 Mar;20(3):322-329. doi: 10.1007/s12094-017-1720-4. Epub 2017 Aug 11.

PMID:
28801777
7.

Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells.

Fatehchand K, Santhanam R, Shen B, Erickson EL, Gautam S, Elavazhagan S, Mo X, Belay T, Tridandapani S, Butchar JP.

PLoS One. 2017 Jul 20;12(7):e0181729. doi: 10.1371/journal.pone.0181729. eCollection 2017.

8.

Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis.

Segarra S, Miró G, Montoya A, Pardo-Marín L, Boqué N, Ferrer L, Cerón J.

Vet Parasitol. 2017 May 30;239:50-56. doi: 10.1016/j.vetpar.2017.04.014. Epub 2017 Apr 23.

10.

Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.

Mathew L, Gaikwad A, Gonzalez A, Nugent EK, Smith JA.

Integr Cancer Ther. 2017 Sep;16(3):300-307. doi: 10.1177/1534735417704948. Epub 2017 Apr 25.

11.
12.

In vivo study of alginate hydrogel conglutinating cells to polycaprolactone vascular scaffolds fabricated by electrospinning.

Sun KH, Liu Z, Liu CJ, Yu T, Zhou M, Liu C, Ran F, Pan LJ, Zhang H.

J Biomed Mater Res B Appl Biomater. 2017 Nov;105(8):2443-2454. doi: 10.1002/jbm.b.33731. Epub 2016 Sep 21.

PMID:
27654960
13.

Active hexose correlated compound modulates LPS-induced hypotension and gut injury in rats.

Doursout MF, Liang Y, Sundaresan A, Wakame K, Fujii H, Takanari J, Devakottai S, Kulkarni A.

Int Immunopharmacol. 2016 Oct;39:280-286. doi: 10.1016/j.intimp.2016.07.023. Epub 2016 Aug 5.

PMID:
27500458
14.

Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.

Zierhut ML, Chen Y, Pithavala YK, Nickens DJ, Valota O, Amantea MA.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):274-82. doi: 10.1002/psp4.12078. Epub 2016 May 15.

15.

Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M.

Nutr Cancer. 2016;68(2):234-40. doi: 10.1080/01635581.2016.1134597. Epub 2016 Feb 4.

PMID:
26847832
16.

AHCC Activation and Selection of Human Lymphocytes via Genotypic and Phenotypic Changes to an Adherent Cell Type: A Possible Novel Mechanism of T Cell Activation.

Olamigoke L, Mansoor E, Mann V, Ellis I, Okoro E, Wakame K, Fuji H, Kulkarni A, Francoise Doursout M, Sundaresan A.

Evid Based Complement Alternat Med. 2015;2015:508746. doi: 10.1155/2015/508746. Epub 2015 Dec 15.

17.
18.

Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.

Palmer DH, Johnson PJ.

Cancer Metastasis Rev. 2015 Sep;34(3):497-509. doi: 10.1007/s10555-015-9580-2. Review.

PMID:
26250585
19.

Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model.

Ignacio RM, Kim CS, Kim YD, Lee HM, Qi XF, Kim SK.

Cytokine. 2015 Dec;76(2):131-137. doi: 10.1016/j.cyto.2015.06.002. Epub 2015 Jun 13.

PMID:
26082022
20.

Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.

Nagai H, Mukozu T, Ogino YU, Matsui D, Matsui T, Wakui N, Momiyama K, Igarashi Y, Sumino Y, Higai K.

Anticancer Res. 2015 Apr;35(4):2269-77.

PMID:
25862889

Supplemental Content

Loading ...
Support Center